|Brief Description||Principal Investigator|
|To describe the anti-tumor activity (efficacy) and toxicity (safety) of commercially available, targeted anti-cancer drugs used for treatment of patients with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known (i) to be a target of an FDA-approved anti-cancer drug or (ii) to predict sensitivity to an FDA-approved anti-cancer drug.||Kim, Edward Sanghyun|
|In the neoadjuvant cohort, to investigate the safety and tolerability of neoadjuvant nivolumab administration in the following tumor types: HPV-positive (SCCHN), HPV-negative (SCCHN), Merkel Cell Carcinoma, Cervical, vaginal, or vulvar cancers. In the metastatic/recurrent cohort, to evaluate the investigator-assessed objective response rate (ORR) of nivolumab monotherapy and combination therapy of Nivolumab and Ipilimumab in subjects with the following diseases: Metastatic or recurrent nasophary||Amin, Asim|
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.
II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.
III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
|Kaplan, Joel Adam|
|To collect tumor samples from EC1456-treated subjects in order to characterize intratumoral EC1456, and metabolites, by liquid chromatography-tandem mass spectrometry (LC-MS/MS).||Naumann, Robert Wendel|
|This trial is studying paclitaxel and carboplatin to see how well they workcompared with bleomycin sulfate, etoposide phosphate, and cisplatin in treating patients with advanced or recurrent sex cord-ovarian stromal tumors.||Brown, Jubilee|
|To compare the objective response rate (ORR) of patients with EOC, primary peritoneal cancer and Fallopian tube cancer randomized to IMGN853 or selected standard of care chemotherapy||Crane, Erin King|
- To evaluate the safety and tolerability of TSR-042 using Common Terminology Criteria for Adverse Events (CTCAE v.4.03) in patients with advanced solid tumors
- To evaluate the antitumor activity of TSR-042 in patients with advanced solid tumors, in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1